Study drug for advanced solid tumors after prior treatments
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign the consent form approved by an ethics committee
- You are age 18 to 80, and your cancer treatment ability is good (ECOG 0 or 1)
- You have an advanced solid cancer diagnosis confirmed by tumor biopsy or cells, and it is not a sarcoma (or it is eligible bladder cancer)
- You have had prior immunotherapy (ICI) or chemotherapy drugs (GC/GP) and you can submit tumor tissue for testing
- You have measurable cancer on scans and are expected to live at least 3 months
- Your organs are functioning well enough for a study drug, and you can avoid certain medicines and vaccines before dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new drug called 9MW2821, alone or with other treatments, for people with advanced solid tumors. It aims to see if the drug can shrink or slow the growth of cancer.
This trial tests a new drug combination for women with advanced gynecologic tumors that have not responded to standard treatments. Participants receive 9MW2821 along with other anti-cancer drugs to see if the combination is safe and effective.
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.